PMID- 33305381
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 48
IP  - 4
DP  - 2021 Apr
TI  - Early add-on administration of mepolizumab and intravenous immunoglobulin 
      effective in treating eosinophilic granulomatosis with polyangiitis.
PG  - 529-532
LID - 10.1111/1346-8138.15709 [doi]
AB  - Treatment of eosinophilic granulomatosis with polyangiitis (EGPA) remains a 
      challenge because currently available therapies, corticosteroids and 
      immunomodulators, do not always control symptoms and are often associated with 
      significant morbidity and relapse. Mepolizumab has been demonstrated to be an 
      effective add-on therapy with steroid-sparing effect in cases of relapsing or 
      refractory EGPA. Intravenous immunoglobulin (IVIG) therapy is effective against 
      mononeuritis multiplex or heart failure in patients with EGPA who do not respond 
      to corticosteroid-cyclophosphamide treatment. We present two cases of EGPA in 
      which earlier add-on administration of adjunct mepolizumab and IVIG led to 
      significant improvement in EGPA symptoms and prevention of flare-up of the 
      disease. We suggested that earlier add-on combination administration of IVIG and 
      mepolizumab might be a useful adjunct treatment to induce clinical remission of 
      EGPA and improve the rate of remission, decrease relapse rate, and allow for 
      reduced glucocorticoid use without any serious adverse drug effects.
CI  - (c) 2020 Japanese Dermatological Association.
FAU - Ikeda, Takaharu
AU  - Ikeda T
AUID- ORCID: 0000-0002-5047-9262
AD  - Division of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, 
      Japan.
FAU - Komatsu, Toshiro
AU  - Komatsu T
AD  - Division of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, 
      Japan.
FAU - Yokoyama, Kae
AU  - Yokoyama K
AD  - Division of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, 
      Japan.
FAU - Takahashi, Kazuo
AU  - Takahashi K
AD  - Division of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, 
      Japan.
FAU - Kawakami, Tamihiro
AU  - Kawakami T
AUID- ORCID: 0000-0001-6741-939X
AD  - Division of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 90Z2UF0E52 (mepolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Churg-Strauss Syndrome/diagnosis/drug therapy
MH  - *Granulomatosis with Polyangiitis
MH  - Humans
MH  - Immunoglobulins, Intravenous
OTO - NOTNLM
OT  - add-on
OT  - eosinophilic granulomatosis with polyangiitis
OT  - intravenous immunoglobulin
OT  - mepolizumab
OT  - vasculitis
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 06:07
PHST- 2020/10/31 00:00 [revised]
PHST- 2020/10/08 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/12/11 06:07 [entrez]
AID - 10.1111/1346-8138.15709 [doi]
PST - ppublish
SO  - J Dermatol. 2021 Apr;48(4):529-532. doi: 10.1111/1346-8138.15709. Epub 2020 Dec 
      10.